BLSM — BlossomHill Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1839970 ·
Last close
$15.13
Market Cap
$480.91M
52W High
$27.99
52W Low
$11.02
ADV30
173,789
Next earnings
2026-11-12
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -24,670,000 -23,758,000 124,131,000 95,376,000 298,911,000
Mar 2026 0 — -22,107,000 -21,008,000 143,410,000 116,003,000 295,530,000
Jun 2025 0 — -14,103,000 -13,244,000 — — —
Mar 2025 0 — -11,454,000 -10,478,000 — — —

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-64,295,000
Investing CF
$-1,010,000
Financing CF
$2,966,000
CapEx
$-1,010,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.92
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-179,795,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-72,334,000
Pretax Income TTM
$-68,488,000
Interest Exp TTM
—
Analysts
5

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -64,024,000 -60,555,000 162,968,000 294,696,000 -131,728,000 -46,925,000
Dec 2024 0 -36,401,000 -30,695,000 106,775,000 179,658,000 -72,883,000 -31,416,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$124,131,000
Forward EPS
$-3.95

Peers — same industry

TickerNameMarket CapLastDaily %
IMMP IMMUTEP Ltd $480.43M $3.26 —
MNPR Monopar Therapeutics $481.56M $71.06 —
NGNE Neurogene Inc. $478.19M $23.10 —
AMRN AMARIN CORP PLC\UK $473.82M $11.27 —
GYRE GYRE THERAPEUTICS, INC. $488.23M $4.56 —

News headlines (Yahoo Finance, 1h cache)

BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-12 21:01 · Yahoo
BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC
2026-11-09 12:00 · Yahoo
BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting
2026-11-04 12:00 · Yahoo
BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference
2026-11-03 12:00 · Yahoo
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
2026-10-22 11:00 · Yahoo
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
2026-09-28 11:00 · Yahoo
BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Update
2026-09-15 14:13 · Yahoo
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
2026-09-03 11:00 · Yahoo
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
2026-09-01 11:00 · Yahoo
Insiders Are Betting Big on These 3 Healthcare Stocks
2026-08-31 17:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.